Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease

17 Oct 2026 0 comments

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Source: NeurologyLive · Published 16 Oct 2026 · Imported 17 Oct 2026

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment